Protalix Ltd.

Biond Biologics Ltd.

Biond Biologies Ltd.

Enzymotec Ltd.

Avidor Shulman

Yoseph Shaaltiel

Dori Pelled

Rassan Zuabi

Zohar Bar-On

Tali Kizhner

Orly Farkash

Ilya Ruderfer

Tehila Ben-Moshe

Yair Sapir

Dana Haves Ziv

Tehila Ben-moshe

Anna Fridman-Dror

Yulia Matiuhin

Yulia Ugortsev

Sivan Gelley

Elad Lavee Laviad

Ilana Mandel

Dorit Platt

Uri Hanania

Ayala Lewkowicz

Talia Shekhter

Yaniv Azulay

Gai Ben-Dror

Liat Fux

Dror Alishekevitz

Motti Hakim

Tsuri Peretz

Ilana Goldshtein

Lilach Chen Zeltsburg

Hagit Neta

Edna Meilin

Tehila Ben Moshe

Rotem Faygenboim-ornai

Yossi Gottfried

Rozi Ravit Uzan Gueta

Orit Shilovitzky

Orit Shilovittzky

The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.

Methods of use for anti-ILT2 antibodies

Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Stabilized alpha-galactosidase and uses thereof

Methods of treating cancer and improving immunotherapies comprising decreasing soluble immune receptor levels are provided. Agents that bind membranal immune receptor and inhibit proteolytic cleavage of the receptor and agents that bind soluble immune receptor and that are neither receptor agonists nor antagonists are also provided, as are methods of producing these agents.

Methods and compositions for decreasing soluble immune receptor CD28

The present disclosure provides monoclonal anti-ILT2 antibodies or antigen-binding fragments thereof, as well as pharmaceutical compositions comprising the same and methods of producing the same. Also provided are methods of treating cancer using the antibodies or compositions of the present disclosure. Methods of patient selection are also provided.

Antibodies against ILT2 and use thereof

Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.

Modified DNase and uses thereof

Antibodies against ILT2

Stabilized &#x3b1;-galactosidase and uses thereof

Nucleic acid expression constructs are provided and, more particularly, nucleic acid constructs for expression of human alpha-galactosidase in plant cells, cells expressing the nucleic acid construct, producing the human alpha-galactosidase and uses thereof.

Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells

DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided.

Dry powder formulations of dNase I

An inhalable pharmaceutical composition for pulmonary administration comprising human DNase I and a liquid carrier and, more particularly, but not exclusively, to methods, liquid pharmaceutical inhalation devices and systems for the therapeutic use thereof are provided.

Inhalable liquid formulations of DNase I

Conjugates of a saccharide and a biomolecule, covalently linked therebetween via a non-hydrophobic linker and methods of preparing same are disclosed. Also disclosed are medical uses utilizing such conjugates. Glycosylation reagents for use in preparing these conjugates are also disclosed. Glycosylated proteins, characterized by improved performance, are also disclosed.

Saccharide-containing protein conjugates and uses thereof

Growing community of inventors

Rakefet, Israel

Avidor Shulman